An optimised dosing regimen versus a standard dosing regimen of vancomycin for the treatment of late onset sepsis due to Gram-positive microorganisms in neonates and infants aged less than 90 days (NeoVanc): study protocol for a randomised controlled tria
Τίτλος | An optimised dosing regimen versus a standard dosing regimen of vancomycin for the treatment of late onset sepsis due to Gram-positive microorganisms in neonates and infants aged less than 90 days (NeoVanc): study protocol for a randomised controlled tria |
Publication Type | Journal Article |
Year of Publication | 2020 |
Authors | Hill, L. F., Turner M. A., Lutsar I., Heath P. T., Hardy P., Linsell L., Jacqz-Aigrain E., Roilides E., & Sharland M. |
Corporate Authors | NeoVanc Consortium |
Journal | Trials |
Volume | 21 |
Issue | 1 |
Pagination | 329 |
Date Published | 2020 Apr 15 |
ISSN | 1745-6215 |
Abstract | BACKGROUND: Vancomycin has been used in clinical practice for over 50 years; however, validated, pharmacokinetic (PK) data relating clinical outcomes to different dosing regimens in neonates are lacking. Coagulase negative staphylococci (CoNS) are the most commonly isolated organisms in neonatal, late-onset sepsis (LOS). Optimised use to maximise efficacy while minimising toxicity and resistance selection is imperative to ensure vancomycin's continued efficacy. |
DOI | 10.1186/s13063-020-4184-8 |
Alternate Journal | Trials |
PubMed ID | 32293527 |
PubMed Central ID | PMC7158076 |
Grant List | 602041 / / FP7 Health / |